Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

287 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study.
Santoni M, Massari F, Myint ZW, Iacovelli R, Pichler M, Basso U, Kopecky J, Kucharz J, Buti S, Rizzo M, Galli L, Büttner T, De Giorgi U, Kanesvaran R, Fiala O, Grande E, Zucali PA, Fornarini G, Bourlon MT, Scagliarini S, Molina-Cerrillo J, Aurilio G, Matrana MR, Pichler R, Cattrini C, Büchler T, Seront E, Calabrò F, Pinto A, Berardi R, Zgura A, Mammone G, Ansari J, Atzori F, Chiari R, Bamias A, Caffo O, Procopio G, Bassanelli M, Merler S, Messina C, Küronya Z, Mosca A, Bhuva D, Vau N, Incorvaia L, Rebuzzi SE, Roviello G, Zabalza IO, Rizzo A, Mollica V, Sorgentoni G, Monteiro FSM, Montironi R, Battelli N, Porta C. Santoni M, et al. Among authors: ansari j. Target Oncol. 2023 Jul;18(4):559-570. doi: 10.1007/s11523-023-00978-2. Epub 2023 Jun 27. Target Oncol. 2023. PMID: 37369815
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1).
Santoni M, Massari F, Myint ZW, Iacovelli R, Pichler M, Basso U, Kopecky J, Kucharz J, Buti S, Salfi A, Büttner T, De Giorgi U, Kanesvaran R, Fiala O, Grande E, Zucali PA, Fornarini G, Bourlon MT, Scagliarini S, Molina-Cerrillo J, Aurilio G, Matrana MR, Pichler R, Cattrini C, Büchler T, Seront E, Calabrò F, Pinto A, Berardi R, Zgura A, Mammone G, Ansari J, Atzori F, Chiari R, Zakopoulou R, Caffo O, Procopio G, Bassanelli M, Zampiva I, Messina C, Küronya Z, Mosca A, Bhuva D, Vau N, Incorvaia L, Rebuzzi SE, Roviello G, Zabalza IO, Rizzo A, Mollica V, Catalini I, Monteiro FSM, Montironi R, Battelli N, Rizzo M, Porta C. Santoni M, et al. Among authors: ansari j. Clin Genitourin Cancer. 2023 Oct;21(5):e309-e319.e1. doi: 10.1016/j.clgc.2023.03.006. Epub 2023 Mar 20. Clin Genitourin Cancer. 2023. PMID: 37062658
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.
Santoni M, Myint ZW, Büttner T, Takeshita H, Okada Y, Lam ET, Gilbert D, Küronya Z, Tural D, Pichler R, Grande E, Crabb SJ, Kemp R, Massari F, Scagliarini S, Iacovelli R, Vau N, Basso U, Maruzzo M, Molina-Cerrillo J, Galli L, Bamias A, De Giorgi U, Zucali PA, Rizzo M, Seront E, Popovic L, Caffo O, Buti S, Kanesvaran R, Kopecky J, Kucharz J, Zeppellini A, Fiala O, Landmesser J, Ansari J, Giannatempo P, Rizzo A, Zabalza IO, Monteiro FSM, Battelli N, Calabrò F, Porta C. Santoni M, et al. Among authors: ansari j. Cancer Immunol Immunother. 2023 Sep;72(9):2961-2970. doi: 10.1007/s00262-023-03469-5. Epub 2023 May 29. Cancer Immunol Immunother. 2023. PMID: 37248424 Free PMC article.
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study.
Roviello G, Molina-Cerrillo J, Massari F, Cerbone L, Fiala O, Fornarini G, Monteiro FSM, Cattrini C, Landmesser J, Messina C, Zgura A, Rebuzzi SE, Soares A, Carrozza F, Ansari J, Grillone F, Küronya Z, Incorvaia L, Bhuva D, Ortega C, Nasso C, Kanesvaran R, Zampiva I, Porta C, Buti S, Santoni M. Roviello G, et al. Among authors: ansari j. Cancer Immunol Immunother. 2025 Jan 3;74(2):65. doi: 10.1007/s00262-024-03897-x. Cancer Immunol Immunother. 2025. PMID: 39752009 Free PMC article.
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study.
Santoni M, Büttner T, Rescigno P, Fiala O, Cavasin N, Basso U, Taha T, Massari F, Myint ZW, Formisano L, Galli L, Scagliarini S, Matrana MR, Facchini G, Bamias A, Messina C, Zacchi F, Manneh RK, Roviello G, Santini D, Poprach A, Navratil J, Uher M, Calabrò F, Pierce E, Berardi R, Aurilio G, Zakopoulou R, Rizzo A, Ansari J, Rizzo M, Bisonni R, Mollica V, Incorvaia L, Spinelli G, Jiang XY, Chandler RA, Grillone F, Morelli F, Buti S, Maluf FC, Marques Monteiro FS, Battelli N, Porta C, Caffo O, Soares A. Santoni M, et al. Among authors: ansari j. Eur Urol Oncol. 2024 Nov 28:S2588-9311(24)00253-0. doi: 10.1016/j.euo.2024.11.005. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39613567 Free article.
287 results